Abstract

BackgroundAlthough long non-coding RNA differentiation antagonizing non-protein coding RNA (DANCR) has been reported to be involved in atherosclerosis (AS) development, its specific mechanism remains unclear.MethodsDANCR expression levels in blood samples of AS patients and oxidized low-density lipoprotein (ox-LDL) treated vascular smooth muscle cells (VSMCs) and human umbilical vein endothelial cells (HUVECs) were detected by quantitative real-time polymerase chain reaction (qRT-PCR). The small interfering RNA targeting DANCR (si-DANCR) was used to silence DANCR expression. Cell viability was assessed by CCK-8 assay. Cell apoptosis was evaluated by flow cytometry. Levels of inflammatory cytokines, anti-oxidative enzyme superoxide dismutase (SOD) activity, and malonaldehyde (MDA) were detected by specific commercial kits. An animal AS model was established to confirm the role of DANCR/microR-214-5p/COX20 (the chaperone of cytochrome c oxidase subunit II COX2) in AS development.ResultsDANCR was significantly increased in the blood samples of AS patients and ox-LDL treated VSMCs and HUVECs. DANCR downregulation obviously increased viability and reduced apoptosis of ox-LDL-treated VSMCs and HUVECs. Meanwhile, DANCR downregulation reduced the levels of inflammatory cytokines, including interleukin (IL)-6 (IL-6), IL-1beta (IL-1β), IL-6 and tumor necrosis factor (TNF)-alpha (TNF-α) and MDA while increasing the SOD level in ox-LDL-treated VSMCs and HUVECs. DANCR regulated COX20 expression by acting as a competing endogenous RNA (ceRNA) of miR-214-5p. Rescue experiments demonstrated that miR-214-5p downregulation obviously attenuated si-DANCR-induced protective effects on ox-LDL-caused endothelial injury.ConclusionsOur results revealed that DANCR promoted AS progression by targeting the miR-214-5p/COX20 axis, suggesting that DANCR might be a potential therapeutic target for AS.

Highlights

  • Atherosclerosis (AS) is a chronic inflammatory disorder and the most common leading cause of cerebrovascular diseases (CVD) [1, 2]

  • We confirmed that differentiation antagonizing nonprotein coding RNA (DANCR) was significantly upregulated in the blood samples of AS patients and oxidized low-density lipoprotein (ox-LDL) treated vascular smooth muscle cells (VSMCs) and human umbilical vein endothelial cells (HUVECs)

  • We stimulated VSMCs and HUVECs with ox-LDL (25, 50, and 100 μg/ml) for 48 h and found that DANCR was significantly upregulated in ox-LDL treated cells (Fig. 1B)

Read more

Summary

Introduction

Atherosclerosis (AS) is a chronic inflammatory disorder and the most common leading cause of cerebrovascular diseases (CVD) [1, 2]. It has been reported that endothelial cell dysfunction is an essential process for AS progression [4]. Understanding the specific molecular mechanisms involved in ox-LDL-induced endothelial cell dysfunction may contribute to developing efficient diagnostic and therapeutic targets for AS. Long non-coding RNAs (lncRNAs), a type of RNA transcripts more than 200 nucleotides in length, have been reported to participate in various biological and pathological processes [6]. Differentiation antagonizing non-protein coding RNA (DANCR), a widely studied lncRNA, has been reported to participate in the development of various human cancers such as non-small cell lung cancer [11] and colorectal cancer [12]. Long non-coding RNA differentiation antagonizing nonprotein coding RNA (DANCR) has been reported to be involved in atherosclerosis (AS) development, its specific mechanism remains unclear

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call